{
    "clinical_study": {
        "@rank": "112542", 
        "acronym": "SEATTLE", 
        "arm_group": [
            {
                "arm_group_label": "ACU-4429 2.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "2.5 mg tablet"
            }, 
            {
                "arm_group_label": "ACU-4429 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "5 mg tablet"
            }, 
            {
                "arm_group_label": "ACU-4429 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "10 mg tablet"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Includes identical tablets with only inactive ingredients (0 mg)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the\n      rate of progression of geographic atrophy compared to placebo in subjects with dry\n      age-related macular degeneration."
        }, 
        "brief_title": "Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Geographic Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Atrophy", 
                "Geographic Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females, age \u226555 years.\n\n          2. Clinical diagnosis of GA associated with AMD\n\n          3. Able and willing to provide written informed consent.\n\n          4. Able to reliably administer oral medication by self or with available assistance.\n\n        Exclusion Criteria:\n\n          1. Active CNV or presence of an active ocular disease.\n\n          2. Known serious allergy to the fluorescein sodium for injection in angiography.\n\n          3. Pre-specified laboratory abnormalities at screening.\n\n          4. Treatment with any investigational study drug within 30 days of screening or device\n             (within 60 days of screening)\n\n          5. History of other disease, metabolic dysfunction, physical examination finding, or\n             clinical laboratory finding\n\n          6. Female subjects who are pregnant or lactating.\n\n          7. Female subjects of childbearing potential and male subjects who are not surgically\n             sterile who are not willing to practice a medically accepted method of birth control\n             from screening through 30 days after completion of the study.\n\n          8. Unstable or poorly controlled medical or ophthalmic conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802866", 
            "org_study_id": "4429-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ACU-4429 2.5 mg", 
                    "ACU-4429 5 mg", 
                    "ACU-4429 10 mg"
                ], 
                "description": "Take orally once daily for 24 months", 
                "intervention_name": "ACU-4429", 
                "intervention_type": "Drug", 
                "other_name": "emixustat hydrochloride"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Take orally once daily for 24 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Geographic atrophy", 
            "GA", 
            "Dry AMD"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Phoenix", 
                    "country": "United States", 
                    "state": "Arizona"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration", 
        "overall_official": {
            "affiliation": "Acucela Inc.", 
            "last_name": "Acucela Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in the total area of the GA lesion(s)", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in BCVA score", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Frequency of AEs, discontinuations due to AEs, or dose modifications; severity and seriousness of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Acucela Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Acucela Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}